Clinical trial
Initial Safety Assessment of SNS-595 for the Treatment of Solid Tumors.
NCT00091585 · Sunesis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00091585 |
|---|---|
| Title | Initial Safety Assessment of SNS-595 for the Treatment of Solid Tumors. |
| Official title | Phase I Open-Label, Multicenter, Dose-Escalation Clinical Study of the Initial Safety and Pharmacokinetic Profiles of Intravenous Administration of SNS-595 in Patients With Advanced Malignancies |
| Lead sponsor | Sunesis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Neoplasms |
| Intervention type | Drug |
| Interventions | SNS-595 |
| Start date | Jun 1, 2004 |
| Completion | Nov 1, 2006 |
| First posted | Sep 14, 2004 |
| Last update posted | May 10, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: